Katherine Bever
SKCCC Johns Hopkins Medical Institution · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institution · Johns Hopkins Medical Institution
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katherine Bever as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06941857 · NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Pancreatic Cancer · principal investigator
- Ph2NCT05014776 · Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph2NCT04209686 · Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Advanced Gastric Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Integration of neo-antigen vaccines and immune checkpoint therapyP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ELIZABETH M. JAFFEE · fiscal years 2021 to 2025Named on NCT05014776
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:56 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 5,520 citationsRCR 184.9
- A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.Clin Cancer Res · 2020118 citationsRCR 4.2
- Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.Clin Cancer Res · 202173 citationsRCR 3.2
- Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram.Biol Psychiatry · 199868 citationsRCR 2.5
- A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages.Oncoimmunology · 202527 citationsRCR 5.5
- A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint.Clin Epigenetics · 202121 citationsRCR 1.0
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.Nat Commun · 202618 citationsRCR 9.0
- Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.Clin Cancer Res · 202515 citationsRCR 2.6
- N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia.Pharmacotherapy · 199710 citationsRCR 0.4
- Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.J Immunother Cancer · 20258 citationsRCR 1.8